- Home
- RFAI vs ACRS Comparison
RFAI vs ACRS Comparison
Compare RFAI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- ACRS
- Stock Information
- Founded
- RFAI 2024
- ACRS 2012
- Country
- RFAI Singapore
- ACRS United States
- Employees
- RFAI N/A
- ACRS N/A
- Industry
- RFAI
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- ACRS Health Care
- Exchange
- RFAI NYSE
- ACRS Nasdaq
- Market Cap
- RFAI 153.1M
- ACRS 132.0M
- IPO Year
- RFAI 2024
- ACRS 2015
- Fundamental
- Price
- RFAI $10.20
- ACRS $2.05
- Analyst Decision
- RFAI
- ACRS Hold
- Analyst Count
- RFAI 0
- ACRS 4
- Target Price
- RFAI N/A
- ACRS $1.00
- AVG Volume (30 Days)
- RFAI 30.6K
- ACRS 1.3M
- Earning Date
- RFAI 01-01-0001
- ACRS 11-06-2024
- Dividend Yield
- RFAI N/A
- ACRS N/A
- EPS Growth
- RFAI N/A
- ACRS N/A
- EPS
- RFAI N/A
- ACRS N/A
- Revenue
- RFAI N/A
- ACRS $27,079,000.00
- Revenue This Year
- RFAI N/A
- ACRS N/A
- Revenue Next Year
- RFAI N/A
- ACRS N/A
- P/E Ratio
- RFAI N/A
- ACRS N/A
- Revenue Growth
- RFAI N/A
- ACRS 26.35
- 52 Week Low
- RFAI $10.00
- ACRS $0.77
- 52 Week High
- RFAI $10.27
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- ACRS 55.69
- Support Level
- RFAI N/A
- ACRS $2.09
- Resistance Level
- RFAI N/A
- ACRS $2.72
- Average True Range (ATR)
- RFAI 0.00
- ACRS 0.26
- MACD
- RFAI 0.00
- ACRS -0.01
- Stochastic Oscillator
- RFAI 0.00
- ACRS 40.71
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.